Unlearn.AI

Selected news for the company - Unlearn.AI, collected since 12/2019. We are still establishing shared news links for this company.

Please provide a valid email address.
Shares Healthcare News With (link):
Other Healthcare Entities

Selected Headlines

Date Headline (link) Source Relevant Snippet
11/10/2020 Carbon Health closes $100M, Buoy Health collects $37.5M and more digital health fundings | MobiHealthNews MobiHealthNews Also: U.K. mental health platform Togetherall raises $10 million; Unlearn.AI adds onto April's Series A with investment from Eisai. 02:40 pm ShareFollowing up on its $28 million add-on investment from May , Carbon Health today announced the close of a $100 million Series C funding round led by Dragoneer Investment Group. The tech-enabled primary care provider's raise also included support from Brookfield Technology Partners, DCVC and Builders VC ...
11/9/2020 The Weekly Notable Startup Funding Report: 11/9/20 alleywatch.com The notable startup fundings for the week ending 11/7/20 featuring funding details for Unlearn.AI , Pony.AI, and three more rounds you must know about. It was a slow week as all eyes were focused on the election. Ayar Labs $35.0M - Series B Emeryville-based Ayar Labs develops an optical I/O solution for applications that require high bandwidth and low latency using light to move data. Founded by Alex Wright Gladstein ...
7/7/2020 5 Q’s for Charles Fisher, CEO of Unlearn.AI datainnovation.org Home Publications Data Innovators 5 Q’s for Charles Fisher, CEO of Unlearn.AI 5 Q’s for Charles Fisher, CEO of Unlearn.AI by Eline Chivot July 7, 2020 The Center for Data Innovation spoke with Charles Fisher, chief executive officer and founder of Unlearn.AI , a U.S. firm that uses AI to build digital replicas of patients in clinical trials. Fisher discussed how this approach can address patient recruitment, one of the main ...
6/15/2020 The Future of Clinical Trials Is Virtual ozy.com ... virus sweeping the planet and its impact. Coronavirus Central: OZY looks at the virus sweeping the planet and its impact. Travel restrictions during the pandemic have affected traditional clinical trials. Startups like Medable and Unlearn.AI are creating platforms for virtual trials instead. These could allow faster clinical trials with larger numbers of participants, potentially allowing cheaper drugs to hit the market more quickly. But virtual trials come with risks too ...
5/20/2020 Trials And Tribulations: Turning Clinical Trials Virtual During COVID-19 crunchbase.com ... usually travel to a clinical site for an in-person evaluation. This is causing principal investigators and research staff to find other ways to keep participants connected with studies. Some startups, including Medable and Unlearn.AI , are working to fix the problems facing clinical trials, from recruiting enough patients to moving toward more virtual aspects. Both received investments within the past few months to help reach those goals. Even before the ...
4/25/2020 Funding Roundup: Company creating ‘digital twins’ for clinical trials raises $12M MedCity News Recruiting for clinical trials can often be challenging, especially for conditions with a limited group of patients. To make the research process a little bit easier, a company called Unlearn.AI is developing a platform to populate control arms with “digital twins.” Unlearn closed a $12 million series A round led by 8VC. As part of the investment, 8VC Principal Francisco Gimenez will join the company’s board of directors. Previous investors ...
4/22/2020 Unlearn.AI Closes $12M Series A Funding finsmes.com ... funding, 8VC Principal Francisco Gimenez, Ph.D., has joined the Unlearn Board of Directors. The company continue to expand operations and its business reach. Founded in 2017 by Charles K. Fisher, Ph.D., founder and CEO, Unlearn.AI leverages its proprietary DiGenesis™ platform which processes historical clinical trial datasets from thousands of patients to build the disease-specific machine learning models used to create Digital Twins and their corresponding virtual medical records. Digital ...
4/21/2020 Unlearn.AI raises $12 million in Series A to advance digital twins for clinical trials luxresearchinc.com ... run studies with regulators and commercial partners to demonstrate the value of digital twins in creating control arms for clinical trials. Unlearn processes historical clinical trial data to build digital twins that... Related companies Unlearn.AI About Lux Research Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and ...
4/21/2020 Unlearn.AI Closes $12M Series A Funding vcnewsdaily.com To export Unlearn.AI Unlearn.AI , developer of the first machine-learning platform that creates Digital Twins used to populate Intelligent Control Arms in clinical studies, today announced that it has closed a $12 million Series A financing. The financing round was led by 8VC with participation from all the company's existing investors including DCVC, DCVC Bio and Mubadala Capital Ventures. Through its investment, 8VC Principal Francisco Gimenez, Ph.D., has joined the ...
4/20/2020 Unlearn.AI nabs $12M to build “digital twins” to speed up and improve clinical trials TechCrunch ... pair. Today, a startup founded by a former principal scientist at Pfizer, which has developed a way of digitising this concept through the use of AI, is announcing some funding to further its efforts. Unlearn.AI , which has built a machine learning platform that builds “digital twin” profiles of patients that become the controls in clinical trials — is announcing that it has raised $12 million in a Series A round. The ...
4/20/2020 Unlearn.AI nabs $12M to build “digital twins” to speed up and improve clinical trials venture.name Menu and widgets Unlearn.AI nabs $12M to build “digital twins” to speed up and improve clinical trials Twins have long played a role in the world of medical research, specifically in the area of clinical trials, where they can help measure the effectiveness of a therapy by applying a control to one of a genetically-similar pair. Today, a startup founded by a former principal scientist at Pfizer, which has ...
4/20/2020 Unlearn.AI nabs $12M to build "digital twins" to speed up and improve clinical trials Yahoo News ... pair. Today, a startup founded by a former principal scientist at Pfizer, which has developed a way of digitising this concept through the use of AI, is announcing some funding to further its efforts. Unlearn.AI , which has built a machine learning platform that builds "digital twin" profiles of patients that become the controls in clinical trials -- is announcing that it has raised $12 million in a Series A round. The ...
4/20/2020 Unlearn.AI nabs $12M to build “digital twins” to speed up and improve clinical trials hedgeaccordingly.com ... pair. Today, a startup founded by a former principal scientist at Pfizer, which has developed a way of digitising this concept through the use of AI, is announcing some funding to further its efforts. Unlearn.AI , which has built a machine learning platform that builds “digital twin” profiles of patients that become the controls in clinical trials — is announcing that it has raised $12 million in a Series A round. The ...
4/20/2020 Unlearn.AI nabs $12M to build "digital twins" to speed up and improve clinical trials dailymagazine.news ... pair. Today, a startup founded by a former principal scientist at Pfizer, which has developed a way of digitising this concept through the use of AI, is announcing some funding to further its efforts. Unlearn.AI , which has built a machine learning platform that builds "digital twin" profiles of patients that become the controls in clinical trials -- is announcing that it has raised $12 million in a Series A round. The ...
4/20/2020 Unlearn.ai raises $12 million to accelerate clinical trials with ‘digital twins’ VentureBeat April 20, 2020 5:00 AM Image Credit: Unlearn Unlearn.ai , a company that designs software tools for clinical research, today announced that it secured $12 million in equity financing. Unlearn’s “digital twin” approach to trials, in which digital models are used in place of real test subjects, could reduce the number of people required to run a trial without sacrificing standards of evidence. Unlearn’s technology could also help to solve the ...
4/20/2020 Clinical Trial Machine Learning Company Unlearn.AI Raises $12 Million pulse2.com Clinical Trial Machine Learning Company Unlearn.AI Raises $12 Million By Noah Long ● April 20, 2020 Clinical Trial Machine Learning Company Unlearn.AI Raises $12 Million Unlearn.AI — the developer of the first machine-learning platform that creates Digital Twins used to populate Intelligent Control Arms in clinical studies — has announced that it has closed a $12 million Series A Unlearn.AI — the developer of the first machine-learning platform that creates Digital Twins ...
4/20/2020 Unlearn.AI Closes $12M Series A to Advance the Use of Digital Twins in Clinical Trials BioSpace Unlearn.AI Closes $12M Series A to Advance the Use of Digital Twins in Clinical Trials Published: Apr 20, 2020 SAN FRANCISCO--( BUSINESS WIRE )-- Unlearn.AI , developer of the first machine-learning platform that creates Digital Twins used to populate Intelligent Control Arms in clinical studies, today announced that it has closed a $12 million Series A financing. The financing round was led by 8VC with participation from all the company’s existing ...
4/20/2020 Unlearn.AI Closes $12 Million Series a to Advance the Use of Digital Twins in Clinical Trials aithority.com ... commercial partners, who are already running studies with Digital Twins and demonstrating their value in generating robust evidence and increasing the potential for trial success,” said Charles K. Fisher, Ph.D ., founder and CEO of Unlearn.AI . “Clinical trials are facing a number of persistent challenges that have only been exacerbated in recent weeks. With support from our forward-thinking investors and industry partners, we are excited to continue growing our exceptional ...
4/20/2020 Unlearn.AI Closes On $12M To Improve Clinical Trials crunchbase.com ... of data, Unlearn aims to reduce the number of patients required to run a trial while maintaining rigorous standards of evidence and study randomization and blinding, said Charles Fisher, Ph.D., founder and CEO of Unlearn.AI . “Patients are limited, which limits the number of trials that we can run,” he said. “If there is a database of 1,000 patients, but you need 1,000 patients for a trial, you can only run ...
4/20/2020 Unlearn.AI nabs $12M to build “digital twins” to speed up and improve clinical trials blogspot.com ... pair. Today, a startup founded by a former principal scientist at Pfizer, which has developed a way of digitising this concept through the use of AI, is announcing some funding to further its efforts. Unlearn.AI , which has built a machine learning platform that builds “digital twin” profiles of patients that become the controls in clinical trials — is announcing that it has raised $12 million in a Series A round. The ...